Skip to content

A Clinical Study to evaluate the effectiveness of Jolly Tulsi 51 drops for Boosting Immune system and Detoxification in healthy subjects.

A Prospective, Interventional Clinical Study to evaluate the efficacy and safety of Jolly Tulsi 51 drops for Boosting Immune system and Detoxification in healthy subjects.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/012126
Enrollment
30
Registered
2018-02-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Jolly Tulsi 51 drops: Dose: 5 drops daily for 56 days oral Control Intervention1: Not Applicable: Not Applicable

Sponsors

Jolly Health Care
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy Male and female subjects who has taken at least 3 course any type antibiotics in the past 3 months. 2.Pregnant women will be included in the study. 3. Mentally, physically and legally eligible to give informed consent. 4. Male and female BMI between 18.0 â?? 30.0 kg/m2 5. Subjects is willing and able to comply with all trial requirements 6. Subjects who have not participated in a similar investigation in the past three months 7. Normal thyroid function

Exclusion criteria

Exclusion criteria: 1. Subjects with history or presence of cancer 2. Subjects with history of a psychiatric disorder and or drug or alcohol abuse or dependency; 3. Subjects having a known intolerance to gluten or lactose 4. Subjects having a known allergy to any ingredient in the investigational product 5. Subjects with Medical history of gastrointestinal bleeding or gastric or duodenal ulcer. 6. Subjects having any other medical condition which, in the opinion of the investigator, could interfere with participation in the study.

Design outcomes

Primary

MeasureTime frame
1. Assessment of aerobic endurance and anaerobic performance by using ergometer from baseline to EOT 2. Assessment of changes quality of life questionnaire from baseline to EOT Timepoint: Screening to End of Treatment

Secondary

MeasureTime frame
1. Incidence and Rate of adverse events. 2. Changes in lab parameters ( Haematology and Liver function test) from baseline to EOT Timepoint: Screening to End of Treatment

Countries

India

Contacts

Public ContactDr Harisha s

ICBio Clinical Research Pvt. Ltd.

harish@icbiocro.com9900111997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026